MeSH term
Frequency | Condition_Probility | Adult | 126 | 0.0 |
Aged | 97 | 0.0 |
Aged, 80 and over | 44 | 0.0 |
*Base Pair Mismatch | 38 | 41.0 |
*DNA Repair | 51 | 7.0 |
DNA-Binding Proteins/analysis | 4 | 5.0 |
Female | 205 | 0.0 |
Humans | 377 | 0.0 |
Immunohistochemistry | 66 | 0.0 |
Male | 172 | 0.0 |
Middle Aged | 155 | 0.0 |
Neoplasm Proteins/analysis | 7 | 2.0 |
Proto-Oncogene Proteins/analysis | 6 | 3.0 |
Research Support, Non-U.S. Gov't | 264 | 0.0 |
Base Sequence | 40 | 0.0 |
DNA Mutational Analysis | 58 | 1.0 |
Genomic Instability | 2 | 12.0 |
Loss of Heterozygosity | 18 | 2.0 |
Microsatellite Repeats/*genetics | 36 | 13.0 |
Molecular Sequence Data | 50 | 0.0 |
Survival Rate | 8 | 0.0 |
Tumor Markers, Biological/genetics/metabolism | 2 | 12.0 |
Age of Onset | 18 | 1.0 |
Amino Acid Sequence | 16 | 0.0 |
Colorectal Neoplasms, Hereditary Nonpolyposis/*genetics/pathology | 4 | 40.0 |
DNA, Neoplasm/chemistry/genetics | 2 | 1.0 |
*DNA-Binding Proteins | 117 | 6.0 |
Family Health | 15 | 1.0 |
Genotype | 12 | 0.0 |
Mutation | 39 | 0.0 |
Neoplasm Proteins/genetics | 53 | 11.0 |
Phenotype | 38 | 0.0 |
Proto-Oncogene Proteins/genetics | 31 | 5.0 |
Sequence Homology, Amino Acid | 11 | 0.0 |
Adenosinetriphosphatase/genetics/metabolism | 2 | 8.0 |
*Aneuploidy | 4 | 4.0 |
Animals | 55 | 0.0 |
*DNA Repair Enzymes | 39 | 40.0 |
DNA-Binding Proteins/genetics/metabolism | 5 | 1.0 |
Exons | 15 | 0.0 |
*Meiosis | 4 | 12.0 |
Mice | 45 | 0.0 |
Mice, Inbred C57BL | 8 | 0.0 |
Mice, Mutant Strains | 5 | 0.0 |
Microsatellite Repeats | 52 | 4.0 |
Neoplasm Proteins/genetics/metabolism | 4 | 3.0 |
Base Pair Mismatch | 50 | 30.0 |
*DNA Methylation | 25 | 3.0 |
Endometrial Neoplasms/*genetics/metabolism/pathology | 2 | 33.0 |
Neoplasm Proteins/biosynthesis/*genetics | 9 | 9.0 |
Promoter Regions (Genetics) | 12 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 123 | 0.0 |
*Germ-Line Mutation | 26 | 6.0 |
Microsatellite Repeats/genetics | 25 | 6.0 |
Predictive Value of Tests | 8 | 0.0 |
Proto-Oncogene Proteins/biosynthesis/*genetics | 5 | 8.0 |
DNA/*metabolism | 3 | 0.0 |
DNA Damage | 5 | 0.0 |
Models, Biological | 4 | 0.0 |
Neoplasms/*genetics | 4 | 1.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 15 | 0.0 |
DNA Repair | 51 | 8.0 |
Immunohistochemistry/methods | 3 | 0.0 |
Tumor Markers, Biological/*analysis | 5 | 0.0 |
Base Pair Mismatch/genetics | 22 | 48.0 |
Child, Preschool | 5 | 0.0 |
DNA Repair/genetics | 36 | 21.0 |
DNA, Neoplasm/*genetics | 4 | 1.0 |
Epigenesis, Genetic | 2 | 7.0 |
Gene Silencing | 4 | 1.0 |
*Genomic Instability | 2 | 15.0 |
Immunoenzyme Techniques | 14 | 0.0 |
Infant | 2 | 0.0 |
Neoplasm Proteins/*genetics/metabolism | 12 | 8.0 |
Polymerase Chain Reaction | 48 | 0.0 |
Promoter Regions (Genetics)/genetics | 8 | 0.0 |
Tumor Cells, Cultured | 24 | 0.0 |
*Adenosinetriphosphatase | 22 | 30.0 |
Cell Line | 20 | 0.0 |
Cisplatin/pharmacology | 4 | 2.0 |
*DNA Damage | 7 | 1.0 |
DNA Primers | 8 | 0.0 |
DNA-Binding Proteins/genetics/*physiology | 2 | 0.0 |
*Escherichia coli Proteins | 3 | 1.0 |
Mice, Knockout | 7 | 0.0 |
Protein p53/metabolism | 4 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 15 | 0.0 |
Colorectal Neoplasms, Hereditary Nonpolyposis/*genetics | 57 | 60.0 |
Conserved Sequence | 2 | 0.0 |
DNA Repair/physiology | 2 | 5.0 |
DNA-Binding Proteins/*genetics/physiology | 3 | 3.0 |
Mutation, Missense | 7 | 0.0 |
Proto-Oncogene Proteins/physiology | 3 | 2.0 |
Base Pair Mismatch/*genetics | 22 | 40.0 |
Colorectal Neoplasms/*genetics | 22 | 10.0 |
Endometrial Neoplasms/*genetics | 8 | 16.0 |
Neoplasms, Multiple Primary/*genetics | 2 | 5.0 |
Case-Control Studies | 7 | 0.0 |
Colorectal Neoplasms, Hereditary Nonpolyposis/ethnology/*genetics | 2 | 66.0 |
Comparative Study | 48 | 0.0 |
Gene Frequency | 5 | 0.0 |
*Genetic Predisposition to Disease | 14 | 1.0 |
Germ-Line Mutation | 39 | 9.0 |
Haplotypes | 4 | 0.0 |
Heterozygote Detection | 4 | 0.0 |
Neoplasm Proteins/*genetics | 79 | 7.0 |
*Polymorphism, Single Nucleotide | 3 | 0.0 |
Crossing Over, Genetic/genetics | 2 | 13.0 |
In Situ Hybridization, Fluorescence | 5 | 0.0 |
Meiosis/*genetics | 3 | 7.0 |
Neoplasm Proteins/metabolism | 7 | 1.0 |
Recombination, Genetic/*genetics | 2 | 2.0 |
Spermatocytes/cytology/metabolism | 2 | 15.0 |
Endometrial Neoplasms/chemistry/*genetics | 2 | 50.0 |
Endometrium/*chemistry | 2 | 8.0 |
*Microsatellite Repeats | 24 | 10.0 |
Neoplasm Proteins/analysis/*genetics | 4 | 12.0 |
Proto-Oncogene Proteins/analysis/*genetics | 2 | 4.0 |
*Drug Resistance, Neoplasm | 2 | 1.0 |
*Antigens, Nuclear | 2 | 1.0 |
CHO Cells | 2 | 0.0 |
*DNA Helicases | 2 | 0.0 |
DNA Repair/*genetics | 45 | 13.0 |
DNA, Complementary/analysis | 2 | 0.0 |
Gene Expression | 10 | 0.0 |
Hamsters | 2 | 0.0 |
*Saccharomyces cerevisiae Proteins | 18 | 1.0 |
Adenosinetriphosphatase/metabolism | 3 | 2.0 |
Cell Nucleus/*metabolism | 2 | 0.0 |
DNA Helicases/metabolism | 2 | 7.0 |
DNA-Binding Proteins/metabolism | 9 | 0.0 |
Fungal Proteins/metabolism | 4 | 2.0 |
Models, Genetic | 8 | 0.0 |
Nuclear Proteins/metabolism | 3 | 0.0 |
Rats | 2 | 0.0 |
*Recombination, Genetic | 5 | 1.0 |
Time Factors | 13 | 0.0 |
Age Factors | 14 | 0.0 |
Cohort Studies | 6 | 0.0 |
Neoplasm Staging | 11 | 0.0 |
Proto-Oncogene Proteins/*genetics | 60 | 6.0 |
Mutation/*physiology | 2 | 1.0 |
Saccharomyces cerevisiae/genetics | 4 | 0.0 |
DNA, Neoplasm/genetics | 18 | 2.0 |
Germ-Line Mutation/*genetics | 15 | 9.0 |
Pedigree | 48 | 0.0 |
Cells, Cultured | 9 | 0.0 |
Cloning, Molecular | 8 | 0.0 |
DNA, Complementary/metabolism | 2 | 0.0 |
Dose-Response Relationship, Drug | 3 | 0.0 |
Electrophoresis, Polyacrylamide Gel | 4 | 0.0 |
Fibroblasts/metabolism | 2 | 0.0 |
Hydrolysis | 2 | 0.0 |
Protein Binding | 5 | 0.0 |
Protein Structure, Tertiary | 2 | 0.0 |
Proteins/metabolism | 3 | 0.0 |
DNA-Binding Proteins/*physiology | 2 | 0.0 |
*Mutation | 29 | 0.0 |
Neoplasm Proteins/*physiology | 3 | 3.0 |
Ultraviolet Rays | 5 | 0.0 |
Colorectal Neoplasms, Hereditary Nonpolyposis/epidemiology/*genetics | 6 | 75.0 |
Genetic Predisposition to Disease | 18 | 0.0 |
Genetic Screening/*methods | 5 | 3.0 |
Sensitivity and Specificity | 17 | 0.0 |
Chromatography, High Pressure Liquid/*methods | 3 | 2.0 |
*DNA Mutational Analysis | 3 | 1.0 |
Polymorphism, Genetic | 8 | 0.0 |
Sequence Analysis, DNA | 12 | 0.0 |
Endometrial Neoplasms/*genetics/pathology | 5 | 15.0 |
English Abstract | 9 | 0.0 |
Receptors, Estrogen/genetics | 2 | 3.0 |
Colorectal Neoplasms/*genetics/pathology | 7 | 8.0 |
Genes, ras | 4 | 1.0 |
O(6)-Methylguanine-DNA Methyltransferase/genetics | 2 | 7.0 |
Colorectal Neoplasms, Hereditary Nonpolyposis/*pathology | 2 | 100.0 |
Neoplasm Proteins/*analysis | 3 | 0.0 |
Proto-Oncogene Proteins/*analysis/genetics | 2 | 6.0 |
Colorectal Neoplasms/genetics | 2 | 4.0 |
Colorectal Neoplasms, Hereditary Nonpolyposis/genetics | 17 | 39.0 |
*Gene Deletion | 6 | 0.0 |
Polymerase Chain Reaction/*methods | 3 | 0.0 |
Frameshift Mutation | 6 | 1.0 |
Neoplasms, Second Primary/*genetics | 2 | 9.0 |
Colonic Neoplasms/pathology | 2 | 3.0 |
Disease Progression | 6 | 0.0 |
Follow-Up Studies | 7 | 0.0 |
DNA-Binding Proteins/*genetics | 28 | 1.0 |
Gene Expression Regulation, Neoplastic | 10 | 0.0 |
*Gene Rearrangement | 2 | 0.0 |
Point Mutation | 6 | 0.0 |
Polymerase Chain Reaction/methods | 7 | 0.0 |
DNA/genetics | 5 | 0.0 |
*Immunoglobulin Class Switching | 2 | 15.0 |
In Vitro | 2 | 0.0 |
Recombination, Genetic | 9 | 0.0 |
Sequence Homology, Nucleic Acid | 6 | 0.0 |
CpG Islands/genetics | 6 | 4.0 |
Colorectal Neoplasms, Hereditary Nonpolyposis/*genetics/*metabolism | 3 | 100.0 |
Mutation/*genetics | 9 | 0.0 |
DNA, Neoplasm/analysis | 17 | 2.0 |
Neoplasm Proteins/genetics/*metabolism | 3 | 1.0 |
Proto-Oncogene Proteins/genetics/metabolism | 6 | 3.0 |
DNA/chemistry/genetics | 3 | 0.0 |
Hela Cells | 7 | 0.0 |
Sequence Analysis, DNA/methods | 2 | 2.0 |
Colorectal Neoplasms/epidemiology/*genetics | 2 | 15.0 |
Endometrial Neoplasms/epidemiology/*genetics | 2 | 50.0 |
*Heterozygote | 8 | 2.0 |
Variation (Genetics)/*genetics | 2 | 0.0 |
Blotting, Western | 7 | 0.0 |
*Mutation, Missense | 4 | 0.0 |
DNA Mutational Analysis/*methods | 5 | 3.0 |
DNA-Binding Proteins/genetics | 15 | 1.0 |
Fungal Proteins/genetics | 6 | 3.0 |
*Genes, Tumor Suppressor | 6 | 0.0 |
Phosphoric Monoester Hydrolases/genetics | 3 | 4.0 |
Plasmids | 2 | 0.0 |
Receptors, Transforming Growth Factor beta/genetics | 2 | 3.0 |
Tumor Suppressor Proteins/genetics | 2 | 2.0 |
Macromolecular Substances | 2 | 0.0 |
Protein Subunits | 2 | 0.0 |
Syndrome | 3 | 0.0 |
Colorectal Neoplasms/metabolism/pathology | 2 | 12.0 |
DNA Repair/*physiology | 7 | 6.0 |
Phosphorylation | 4 | 0.0 |
Thioguanine/pharmacology | 2 | 11.0 |
Genes, p53 | 7 | 1.0 |
Neoplasm Proteins/genetics/*physiology | 3 | 6.0 |
Alleles | 20 | 0.0 |
Colectomy | 2 | 7.0 |
Colonoscopy | 4 | 9.0 |
CpG Islands/*genetics | 3 | 3.0 |
DNA Primers/genetics | 2 | 0.0 |
Intestinal Mucosa/pathology | 2 | 3.0 |
Mass Screening | 3 | 1.0 |
Risk Assessment | 5 | 0.0 |
Codon | 2 | 0.0 |
Child | 14 | 0.0 |
Rectal Neoplasms/*genetics/pathology | 2 | 22.0 |
Prospective Studies | 6 | 0.0 |
Prognosis | 16 | 0.0 |
Survival Analysis | 9 | 0.0 |
Disease-Free Survival | 5 | 0.0 |
Retrospective Studies | 5 | 0.0 |
Adolescent | 15 | 0.0 |
Heterozygote | 16 | 0.0 |
Netherlands/epidemiology | 2 | 1.0 |
Registries | 3 | 1.0 |
Risk Factors | 13 | 0.0 |
Sex Factors | 4 | 0.0 |
Fungal Proteins/*genetics | 11 | 9.0 |
Gene Deletion | 11 | 0.0 |
Reproducibility of Results | 3 | 0.0 |
Colonic Neoplasms/*genetics/metabolism/pathology | 2 | 10.0 |
Genes, APC | 3 | 3.0 |
Tumor Markers, Biological/metabolism | 2 | 0.0 |
*Codon, Nonsense | 2 | 3.0 |
Colorectal Neoplasms, Hereditary Nonpolyposis/*genetics/metabolism | 4 | 100.0 |
*Exons | 2 | 0.0 |
RNA, Messenger/biosynthesis/genetics | 2 | 0.0 |
Genetic Screening | 15 | 1.0 |
Incidence | 9 | 0.0 |
Neoplasm Proteins/biosynthesis/genetics | 5 | 3.0 |
Proto-Oncogene Proteins/biosynthesis/genetics | 7 | 8.0 |
DNA Methylation | 10 | 1.0 |
Glioblastoma/*genetics | 2 | 2.0 |
Protein p53/genetics | 2 | 1.0 |
3T3 Cells | 2 | 0.0 |
Chromosome Painting | 2 | 4.0 |
DNA-Binding Proteins/genetics/*metabolism | 4 | 0.0 |
Meiosis/genetics | 3 | 10.0 |
*Nuclear Proteins | 2 | 0.0 |
Tissue Distribution | 2 | 0.0 |
Transcription, Genetic | 4 | 0.0 |
Transfection | 6 | 0.0 |
Neoplasm Proteins/*metabolism | 11 | 2.0 |
Proto-Oncogene Proteins/*metabolism | 5 | 0.0 |
DNA Topoisomerases, Type II/*antagonists & inhibitors | 2 | 8.0 |
Doxorubicin/pharmacology | 3 | 1.0 |
Drug Resistance, Neoplasm | 3 | 0.0 |
Ovarian Neoplasms/*genetics | 2 | 0.0 |
Gene Expression Regulation, Neoplastic/genetics | 4 | 2.0 |
*Gene Silencing | 2 | 1.0 |
Promoter Regions (Genetics)/*genetics | 2 | 0.0 |
Germ-Line Mutation/genetics | 7 | 10.0 |
Exons/genetics | 5 | 0.0 |
Ploidies | 3 | 1.0 |
Likelihood Functions | 2 | 1.0 |
*Variation (Genetics) | 2 | 0.0 |
Breast Neoplasms/genetics | 2 | 0.0 |
Genes, BRCA1 | 3 | 1.0 |
Ovarian Neoplasms/genetics | 3 | 1.0 |
Carcinoma/*genetics/pathology | 2 | 3.0 |
*Gene Expression Regulation, Neoplastic | 7 | 0.0 |
Neoplasm Proteins/*biosynthesis | 5 | 5.0 |
Neoplasms, Multiple Primary/*genetics/pathology | 2 | 20.0 |
Proto-Oncogene Proteins/*biosynthesis | 5 | 3.0 |
Genetic Screening/methods | 5 | 4.0 |
Breast Neoplasms/*genetics | 2 | 0.0 |
*Frameshift Mutation | 2 | 1.0 |
DNA/genetics/metabolism | 2 | 0.0 |
Tumor Markers, Biological/*metabolism | 2 | 0.0 |
Diagnosis, Differential | 4 | 0.0 |
Genetic Predisposition to Disease/genetics | 3 | 0.0 |
Netherlands | 2 | 1.0 |
Penetrance | 2 | 1.0 |
Colonic Neoplasms/*genetics/pathology | 2 | 4.0 |
Genes, ras/genetics | 2 | 1.0 |
Multivariate Analysis | 4 | 0.0 |
Statistics, Nonparametric | 4 | 0.0 |
Colonic Neoplasms/genetics | 4 | 6.0 |
Endometrial Neoplasms/genetics | 4 | 25.0 |
Rectal Neoplasms/genetics | 2 | 22.0 |
Stomach Neoplasms/genetics | 3 | 12.0 |
Urologic Neoplasms/genetics | 2 | 100.0 |
*Genes, p53 | 2 | 0.0 |
Codon, Terminator/genetics | 2 | 3.0 |
Colonic Neoplasms/drug therapy/genetics | 2 | 50.0 |
Oligonucleotide Array Sequence Analysis | 4 | 0.0 |
Blotting, Northern | 3 | 0.0 |
DNA, Neoplasm/*analysis | 5 | 2.0 |
*Gene Expression Profiling | 2 | 0.0 |
Cell Nucleus/metabolism | 4 | 0.0 |
DNA Replication | 5 | 1.0 |
Precipitin Tests | 3 | 0.0 |
*CpG Islands | 2 | 2.0 |
Precancerous Conditions/genetics | 2 | 9.0 |
Cytogenetic Analysis/methods | 2 | 12.0 |
In Situ Hybridization, Fluorescence/*methods | 2 | 2.0 |
Synaptonemal Complex/*genetics | 2 | 100.0 |
Carrier Proteins/*genetics | 2 | 0.0 |
Chromatography, High Pressure Liquid | 3 | 0.0 |
Loss of Heterozygosity/genetics | 5 | 3.0 |
Nucleic Acid Denaturation | 4 | 4.0 |
United States | 2 | 0.0 |
Crosses, Genetic | 5 | 0.0 |
Intestinal Neoplasms/genetics | 2 | 50.0 |
Mice, Inbred BALB C | 4 | 0.0 |
Mice, Transgenic | 2 | 0.0 |
*Point Mutation | 4 | 0.0 |
DNA, Neoplasm/*genetics/metabolism | 2 | 18.0 |
Gene Expression Profiling | 2 | 0.0 |
Dimerization | 6 | 0.0 |
Tumor Markers, Biological/*biosynthesis | 2 | 2.0 |
Colorectal Neoplasms, Hereditary Nonpolyposis/genetics/pathology | 4 | 57.0 |
*Loss of Heterozygosity | 6 | 1.0 |
DNA Mutational Analysis/methods | 4 | 1.0 |
Sequence Analysis, RNA/*methods | 2 | 40.0 |
*Sequence Deletion | 4 | 1.0 |
Cytoskeletal Proteins/*biosynthesis | 2 | 11.0 |
*Immunohistochemistry | 2 | 2.0 |
Neoplasm Metastasis | 2 | 0.0 |
Linkage (Genetics) | 7 | 0.0 |
*Multidrug Resistance-Associated Proteins | 6 | 11.0 |
Cell Cycle/drug effects | 3 | 0.0 |
Drug Screening Assays, Antitumor | 2 | 0.0 |
Hydrogen Peroxide/toxicity | 2 | 8.0 |
Peroxides/*toxicity | 2 | 50.0 |
Gene Expression Regulation, Neoplastic/*genetics | 2 | 1.0 |
Lymphatic Metastasis | 4 | 0.0 |
Neoplasm Proteins/deficiency/*genetics | 2 | 22.0 |
CpG Islands | 3 | 1.0 |
*Neoplasm Proteins | 10 | 1.0 |
Proto-Oncogene Proteins/genetics/*metabolism | 2 | 0.0 |
Regression Analysis | 2 | 0.0 |
Adenomatous Polyposis Coli Protein | 4 | 5.0 |
Neoplasm Proteins/biosynthesis | 2 | 2.0 |
Protein Biosynthesis | 4 | 0.0 |
Recurrence | 2 | 0.0 |
Colorectal Neoplasms, Hereditary Nonpolyposis/diagnosis/*genetics | 10 | 83.0 |
Proto-Oncogene Proteins/analysis/genetics | 4 | 14.0 |
Enzyme Inhibitors/pharmacology | 3 | 0.0 |
Fluorescent Antibody Technique | 4 | 0.0 |
DNA-Binding Proteins/biosynthesis/*genetics | 3 | 2.0 |
In Situ Hybridization | 2 | 0.0 |
Risk | 4 | 0.0 |
*Acid Anhydride Hydrolases | 4 | 1.0 |
*Chromosomes, Human, Pair 3 | 3 | 0.0 |
DNA/metabolism | 4 | 0.0 |
Down-Regulation | 2 | 0.0 |
Hybrid Cells | 3 | 0.0 |
Mice, SCID | 2 | 0.0 |
Proteins/*genetics | 8 | 0.0 |
Genetic Markers | 9 | 0.0 |
Tumor Markers, Biological/analysis | 2 | 0.0 |
Dacarbazine/*analogs & derivatives/pharmacology | 3 | 27.0 |
Drug Resistance, Neoplasm/*genetics | 2 | 2.0 |
Dinucleotide Repeats | 3 | 3.0 |
Colonic Neoplasms/*genetics | 3 | 3.0 |
Mutation/genetics | 7 | 0.0 |
Polymorphism, Single-Stranded Conformational | 12 | 0.0 |
*Polymorphism, Genetic | 6 | 0.0 |
Antineoplastic Agents/pharmacology | 3 | 0.0 |
Carboplatin/pharmacology | 2 | 22.0 |
Alternative Splicing/*genetics | 3 | 1.0 |
Protein-Serine-Threonine Kinases/genetics | 2 | 1.0 |
Proteins/genetics | 11 | 1.0 |
Variation (Genetics) | 3 | 0.0 |
BRCA2 Protein | 5 | 0.0 |
Breast Neoplasms/diagnosis/*genetics | 2 | 7.0 |
Transcription Factors/genetics | 3 | 0.0 |
Neoplasm Invasiveness | 3 | 0.0 |
DNA, Neoplasm/genetics/metabolism | 2 | 2.0 |
Transcription Factors/*genetics | 2 | 0.0 |
History, 19th Century | 3 | 10.0 |
History, 20th Century | 3 | 2.0 |
Colorectal Neoplasms/*genetics/metabolism | 3 | 9.0 |
Sequence Deletion/genetics | 2 | 1.0 |
DNA/analysis | 3 | 0.0 |
DNA Primers/chemistry | 3 | 0.0 |
Evolution, Molecular | 3 | 0.0 |
*Founder Effect | 3 | 2.0 |
Introns | 4 | 0.0 |
Finland/epidemiology | 3 | 2.0 |
Herpesvirus 4, Human/genetics | 2 | 2.0 |
Cell Cycle Proteins/metabolism | 3 | 0.0 |
Signal Transduction | 2 | 0.0 |
Colorectal Neoplasms/diagnosis/*genetics | 3 | 33.0 |
Genome, Human | 3 | 0.0 |
Adenocarcinoma/*genetics | 2 | 1.0 |
Diploidy | 3 | 2.0 |
Chromosomal Instability/genetics | 2 | 66.0 |
Colorectal Neoplasms, Hereditary Nonpolyposis/complications/*genetics | 2 | 100.0 |
Family | 4 | 1.0 |
Proto-Oncogene Proteins/metabolism | 4 | 0.0 |
RNA, Messenger/biosynthesis | 3 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction/methods | 3 | 0.0 |
Karyotyping | 3 | 0.0 |
Mutation, Missense/*genetics | 2 | 1.0 |
Fungal Proteins/*genetics/physiology | 2 | 22.0 |
DNA, Complementary/genetics | 2 | 0.0 |
DNA-Binding Proteins/*biosynthesis | 3 | 2.0 |
Electrophoresis, Gel, Two-Dimensional | 3 | 0.0 |
Saccharomyces cerevisiae/*genetics | 6 | 3.0 |
Mice, Inbred Strains | 2 | 0.0 |
RNA, Messenger/genetics | 2 | 0.0 |
Species Specificity | 3 | 0.0 |
Portugal | 2 | 3.0 |
Genes, BRCA1/genetics | 2 | 2.0 |
Genetic Predisposition to Disease/*genetics | 4 | 1.0 |
Great Britain/epidemiology | 2 | 1.0 |
Odds Ratio | 2 | 0.0 |
Chromosome Aberrations | 2 | 0.0 |
Neoplasm Proteins/analysis/genetics | 2 | 8.0 |
Genetic Markers/genetics | 4 | 0.0 |
Colorectal Neoplasms, Hereditary Nonpolyposis/*diagnosis/genetics | 2 | 100.0 |
Genetic Techniques | 2 | 2.0 |
*Genetic Screening | 7 | 3.0 |
DNA, Satellite/genetics | 3 | 2.0 |
Genetic Complementation Test | 3 | 0.0 |
Neoplasm Proteins | 3 | 9.0 |
Adenomatous Polyposis Coli/genetics | 3 | 10.0 |
Cell Survival | 2 | 0.0 |
Chromosome Mapping | 6 | 0.0 |
Chromosomes, Human, Pair 3 | 4 | 2.0 |
*Carrier Proteins | 11 | 1.0 |
Immunoglobulin Class Switching/*genetics | 2 | 20.0 |
Italy/epidemiology | 3 | 1.0 |
Cytoskeletal Proteins/genetics | 2 | 3.0 |
Protein Synthesis Inhibitors/pharmacology | 2 | 0.0 |
Radiation, Ionizing | 3 | 2.0 |
*Alleles | 5 | 0.0 |
Neoplasms, Experimental/*genetics | 2 | 16.0 |
Kinetics | 2 | 0.0 |
Sequence Alignment | 3 | 0.0 |
Cytoskeletal Proteins/*genetics | 2 | 1.0 |
*Genes, APC | 3 | 3.0 |
*Mutagenesis | 2 | 3.0 |
Methylation | 3 | 0.0 |
*Promoter Regions (Genetics) | 5 | 0.0 |
DNA Transposable Elements | 2 | 1.0 |
Sequence Deletion | 3 | 0.0 |
Tumor Cells, Cultured/drug effects | 2 | 0.0 |
Endometrial Neoplasms/complications/*genetics | 2 | 66.0 |
Genes, Tumor Suppressor | 5 | 0.0 |
Probability | 2 | 0.0 |
Tumor Markers, Biological/genetics | 2 | 2.0 |
Logistic Models | 2 | 0.0 |
DNA Replication/genetics | 2 | 3.0 |
DNA-Binding Proteins/*metabolism | 4 | 0.0 |
Transcription, Genetic/genetics | 2 | 0.0 |
*Proto-Oncogene Proteins | 8 | 0.0 |
Haploidy | 2 | 1.0 |
Genes, Tumor Suppressor/genetics | 2 | 1.0 |
DNA, Neoplasm | 4 | 3.0 |
DNA-Binding Proteins/*genetics/metabolism | 5 | 1.0 |
Proto-Oncogene Proteins/*genetics/metabolism | 3 | 2.0 |
RNA, Messenger/metabolism | 3 | 0.0 |
Cell Line, Tumor | 7 | 0.0 |
Homozygote | 2 | 0.0 |
Neurofibromatosis 1/*genetics | 2 | 1.0 |
Colorectal Neoplasms/*genetics/*pathology | 2 | 8.0 |
Statistics | 2 | 0.0 |
DNA Repair/genetics/*physiology | 2 | 9.0 |
Oligonucleotide Probes/genetics | 2 | 1.0 |
DNA-Binding Proteins/*analysis | 2 | 3.0 |
Proteins/*analysis | 2 | 1.0 |
Disease Susceptibility | 6 | 0.0 |
Neoplasm Proteins/*deficiency/genetics | 2 | 33.0 |
Organ Specificity | 2 | 0.0 |
RNA, Messenger/analysis | 3 | 0.0 |
Protein p53/physiology | 2 | 2.0 |
Fungal Proteins/genetics/*metabolism | 2 | 3.0 |
Nucleic Acid Heteroduplexes | 3 | 6.0 |
Genes, p16 | 3 | 3.0 |
Blotting, Southern | 3 | 0.0 |
Gene Amplification | 2 | 0.0 |
RNA-Directed DNA Polymerase | 2 | 1.0 |
Gene Rearrangement | 2 | 0.0 |
Cell Differentiation | 3 | 0.0 |
Finland | 2 | 0.0 |
Genes, Fungal | 3 | 2.0 |
Mutagenesis | 5 | 0.0 |
DNA, Fungal/genetics | 3 | 5.0 |
*Genes, Fungal | 3 | 2.0 |
Chi-Square Distribution | 2 | 0.0 |
*Repetitive Sequences, Nucleic Acid | 4 | 1.0 |
Neoplasms/genetics | 3 | 2.0 |
Genetic Counseling | 2 | 1.0 |
Cell Transformation, Neoplastic/genetics | 2 | 0.0 |
Chromosome Deletion | 3 | 0.0 |
*Caenorhabditis elegans Proteins | 4 | 3.0 |
Colorectal Neoplasms, Hereditary Nonpolyposis/blood/*genetics | 2 | 100.0 |
*Gene Conversion | 2 | 6.0 |
*Homozygote | 2 | 1.0 |
Cell Transformation, Neoplastic | 2 | 0.0 |
Lymphatic Metastasis/pathology | 2 | 2.0 |
Neoplasm Invasiveness/pathology | 2 | 3.0 |
Neoplasm Proteins/*deficiency/physiology | 2 | 100.0 |
Protein p53/*genetics | 2 | 1.0 |
Sex Distribution | 3 | 1.0 |
Cost-Benefit Analysis | 3 | 2.0 |
Carcinoma/*genetics | 2 | 1.0 |
Protein p53/*metabolism | 2 | 0.0 |
Adenosinetriphosphatase/*genetics/metabolism | 2 | 7.0 |
Mass Screening/methods | 2 | 4.0 |
Age Distribution | 2 | 0.0 |
Genetic Predisposition to Disease/*ethnology | 2 | 16.0 |
Jews/*genetics | 3 | 2.0 |
United States/epidemiology | 2 | 0.0 |
Colorectal Neoplasms, Hereditary Nonpolyposis/*epidemiology/*genetics | 2 | 66.0 |
Gene Expression Regulation/*drug effects | 2 | 0.0 |
